Skip to main content Back to Top

Clinician Perspectives on the Impact of Pharmacogenetics on Treating Patients With Coronavirus

Broadcast Date: July 22, 2020


Subscribe on iTune PodcastsListen on Google PlaySubscribe to Stitcher Podcasts Listen on Spotify Subscribe to TuneIn PodcastsSubscribe to iHeartRadio

We chat with Cyrine Haidar and Kelly Caudle about implications and the use of pharmacogenetics in treating patients with coronavirus.


Cyrine HaidarCyrine Haidar is the Clinical Pharmacogenetics Coordinator at St. Jude Children's Research Hospital in Memphis, TN. Dr. Haidar is the program coordinator for St. Jude’s ASHP-accredited PGY2 Clinical Pharmacogenomics Residency and an Assistant Professor of Clinical Pharmacy at The University of Tennessee Health Science Center. She earned her Bachelor of Pharmacy and Pharmacy Doctorate degrees from the Lebanese American University in Byblos, Lebanon. She completed a pharmacotherapy (PGY1) residency at Hackensack University Medical Center and a Pediatric Oncology residency at St. Jude Children’s Research Hospital. She has been at St. Jude Children's Research Hospital since 2004 initially serving as a clinical pharmacy specialist and subsequently joining the clinical pharmacogenomics service. She is also an assistant professor at the University Of Tennessee College Of Pharmacy. Dr. Haidar’s main job functions include translating the scientific knowledge gained in pharmacogenomics into clinical practice. Her primary research interests are in in the fields of pediatric cancers and pharmacogenomics. She is an active member of the Clinical Pharmacogenetics Implementation Consortium (CPIC) and has authored 5 CPIC guidelines to date. She has been an invited speaker at multiple national and international meetings to discuss St. Jude’s use of preemptive pharmacogenetics. She serves on the Board of Directors of the Board of Pharmacy Specialties and is double board certified (BPS) in Pharmacotherapy and Oncology.

Kelly CaudleKelly E. Caudle, Pharm.D., Ph.D., BCPS is the Clinical Pharmacogenetics Implementation Consortium (CPIC) Co-PI and Director. CPIC provides guidelines that enable the translation of genetic laboratory test results into actionable prescribing decisions for specific drugs. To date, CPIC has published 25 gene-based clinical guidelines. In this position, Dr. Caudle oversees the CPIC guideline development process including the coordination of the guideline writing committees, the guideline evidence reviews, and the writing of the guideline manuscript and supplement. Furthermore, Dr. Caudle is involved in the clinical implementation of pharmacogenetics at St. Jude Children's Research Hospital.

Vicki BasalygaVicki Basalyga, Pharm.D., BCPS, BCPPS, is the Director for the Section of Clinical Specialists and Scientists. In this role Vicki serves as an information resource and provides guidance to ASHP members regarding science and scientific developments affecting pharmacy practice in health systems. She serves as secretary to the Section executive committee and coordinates activities to accomplish the objectives established by the Section. Additionally, Vicki has assumed the position of Council Secretary for the ASHP's Council on Therapeutics.

Vicki received her Doctor of Pharmacy from Duquesne University and completed an ASHP accredited PGY1 at Children’s National Medical Center in Washington, DC. Vicki is also a Board Certified Pharmacotherapy Specialist and a Board Certified Pediatric Pharmacotherapy Specialist.

Prior to her current position at ASHP, Vicki practiced as critical care pharmacist in both the Cardiac Intensive Care Unit and the Pediatric Intensive Care Unit at Children’s National Medical Center in Washington, DC. Other activities Vicki performed included drafting policies and procedures, co-chairing the Antimicrobial Stewardship Program, creating and drafting order sets for CPOE conversion and precepting residents and students.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.